Pael receptor is involved in dopamine metabolism in the nigrostriatal system

Neuroscience Research

Volumn 59, Issue 4, 2007, Pages 413-425

  Imai, Yuzuru ^a   Inoue, Haruhisa ^a   Kataoka, Ayane ^a   Hua Qin, Wang ^a   Masuda, Masao ^b   Ikeda, Toshio ^a   Tsukita, Kayoko ^a   Soda, Mariko ^a   Kodama, Tohru ^c   Fuwa, Tatsu ^c   Honda, Yoshiko ^c   Kaneko, Satoshi ^d   Matsumoto, Sadayuki ^d   Wakamatsu, Kazumasa ^e   Ito, Shosuke ^e   Miura, Masami ^b   Aosaki, Toshihiko ^b   Itohara, Shigeyoshi ^a   Takahashi, Ryosuke ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d Kitano Hospital   (Japan)

^e FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

6 OHDA; AR JP; GPR37; MPTP; Parkin; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; PAEL RECEPTOR; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NEUROCHEMISTRY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; DRUG RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURAL PATHWAYS; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RECEPTORS, G-PROTEIN-COUPLED; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 35548936908     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.08.005     Document Type: Article

References (47)

1. Bamford N.S., Zhang H., Schmitz Y., Wu N.P., Cepeda C., Levine M.S., Schmauss C., Zakharenko S.S., Zablow L., and Sulzer D. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42 (2004) 653-663
2. Ben-Shachar D., Zuk R., Gazawi H., and Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 67 (2004) 1965-1974
3. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
4. Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S., and Price D.L. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. 13 (1996) 159-163
5. Calabresi P., Fedele E., Pisani A., Fontana G., Mercuri N.B., Bernardi G., and Raiteri M. Transmitter release associated with long-term synaptic depression in rat corticostriatal slices. Eur. J. Neurosci. 7 (1995) 1889-1894
6. Cantuti-Castelvetri I., Shukitt-Hale B., and Joseph J.A. Dopamine neurotoxicity: age-dependent behavioral and histological effects. Neurobiol. Aging 24 (2003) 697-706
7. Centonze D., Picconi B., Baunez C., Borrelli E., Pisani A., Bernardi G., and Calabresi P. Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology 26 (2002) 164-175
8. Centonze D., Grande C., Usiello A., Gubellini P., Erbs E., Martin A.B., Pisani A., Tognazzi N., Bernardi G., Moratalla R., Borrelli E., and Calabresi P. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J. Neurosci. 23 (2003) 6245-6254
9. Centonze D., Gubellini P., Usiello A., Rossi S., Tscherter A., Bracci E., Erbs E., Tognazzi N., Bernardi G., Pisani A., Calabresi P., and Borrelli E. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience 129 (2004) 157-166
10. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., Suzuki H., Araki W., Inoue H., Shirotani K., Takahashi K., Gallyas F., and Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5 (1999) 560-564
11. Donohue P.J., Shapira H., Mantey S.A., Hampton L.L., Jensen R.T., and Battey J.F. A human gene encodes a putative G protein-coupled receptor highly expressed in the central nervous system. Brain Res. Mol. Brain Res. 54 (1998) 152-160
12. Fornai F., Lenzi P., Gesi M., Soldani P., Ferrucci M., Lazzeri G., Capobianco L., Battaglia G., De Blasi A., Nicoletti F., and Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88 (2004) 114-123
13. Fumagalli F., Gainetdinov R.R., Valenzano K.J., and Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18 (1998) 4861-4869
14. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., and Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 (2003) 43628-43635
15. Gomi H., Yokoyama T., Fujimoto K., Ikeda T., Katoh A., Itoh T., and Itohara S. Mice devoid of the glial fibrillary acidic protein develop normally and are susceptible to scrapie prions. Neuron 14 (1995) 29-41
16. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1956-1961
17. Imai Y., Soda M., and Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275 (2000) 35661-35664
18. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., and Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 (2001) 891-902
19. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., and Takahashi R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell. 10 (2002) 55-67
20. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M.J., Canals S., Solano R., Serrano A., Gallego E., Sanchez M., Denefle P., Benavides J., Tremp G., Rooney T.A., Brice A., and Garcia de Yebenes J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12 (2003) 2277-2291
21. Ito S., Kato T., and Fujita K. Covalent binding of catechols to proteins through the sulphydryl group. Biochem. Pharmacol. 37 (1988) 1707-1710
22. Kaneko S., Hikida T., Watanabe D., Ichinose H., Nagatsu T., Kreitman R.J., Pastan I., and Nakanishi S. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 289 (2000) 633-637
23. Kawasawa Y., McKenzie L.M., Hill D.P., Bono H., and Yanagisawa M. G protein-coupled receptor genes in the FANTOM2 database. Genome Res. 13 (2003) 1466-1477
24. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
25. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
26. Lee C.K., Weindruch R., and Prolla T.A. Gene-expression profile of the ageing brain in mice. Nat. Genet. 25 (2000) 294-297
27. Lu T., Pan Y., Kao S.Y., Li C., Kohane I., Chan J., and Yankner B.A. Gene regulation and DNA damage in the ageing human brain. Nature 429 (2004) 883-891
28. Marazziti D., Gallo A., Golini E., Matteoni R., and Tocchini-Valentini G.P. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. Genomics 53 (1998) 315-324
29. Marazziti D., Golini E., Mandillo S., Magrelli A., Witke W., Matteoni R., and Tocchini-Valentini G.P. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10189-10194
30. Marazziti D., Mandillo S., Di Pietro C., Golini E., Matteoni R., and Tocchini-Valentini G.P. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 9846-9851
31. Masserano J.M., Gong L., Kulaga H., Baker I., and Wyatt R.J. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharmacol. 50 (1996) 1309-1315
32. Murakami T., Shoji M., Imai Y., Inoue H., Kawarabayashi T., Matsubara E., Harigaya Y., Sasaki A., Takahashi R., and Abe K. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann. Neurol. 55 (2004) 439-442
33. Nelson E.L., Liang C.L., Sinton C.M., and German D.C. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369 (1996) 361-371
34. Rabinovic A.D., Lewis D.A., and Hastings T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101 (2000) 67-76
35. Rezgaoui M., Susens U., Ignatov A., Gelderblom M., Glassmeier G., Franke I., Urny J., Imai Y., Takahashi R., and Schaller H.C. The neuropeptide head activator is a high-affinity ligand for the orphan G-protein-coupled receptor GPR37. J. Cell. Sci. 119 (2006) 542-549
36. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
37. Sunaga S., Maki K., Komagata Y., Ikuta K., and Miyazaki J.I. Efficient removal of loxP-flanked DNA sequences in a gene-targeted locus by transient expression of Cre recombinase in fertilized eggs. Mol. Reprod. Dev. 46 (1997) 109-113
38. Tateno M., Sadakata H., Tanaka M., Itohara S., Shin R.M., Miura M., Masuda M., Aosaki T., Urushitani M., Misawa H., and Takahashi R. Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum. Mol. Genet. 13 (2004) 2183-2196
39. Valdenaire O., Giller T., Breu V., Ardati A., Schweizer A., and Richards J.G. A new family of orphan G protein-coupled receptors predominantly expressed in the brain. FEBS Lett. 424 (1998) 193-196
40. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22 (1999) 51-61
41. Wieczorek W.J., and Kruk Z.L. A quantitative comparison on the effects of benztropine, cocaine and nomifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice. Brain Res. 657 (1994) 42-50
42. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
43. Yanagawa Y., Kobayashi T., Ohnishi M., Tamura S., Tsuzuki T., Sanbo M., Yagi T., Tashiro F., and Miyazaki J. Enrichment and efficient screening of ES cells containing a targeted mutation: the use of DT-A gene with the polyadenylation signal as a negative selection maker. Transgenic Res. 8 (1999) 215-221
44. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
45. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13354-13359
46. Zhou Q.Y., and Palmiter R.D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83 (1995) 1197-1209
47. Zigmond M.J., Hastings T.G., and Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism Relat. Disord. 8 (2002) 389-393